Methylenedioxynitazene is a synthetic opioid belonging to the nitazene family of benzimidazole derivatives. It is structurally related to the earlier‑developed analgesic compounds such as etonitazene and isotonitazene, with the distinguishing feature of a methylenedioxy substituent on the phenyl ring of the molecule.
Chemical Characteristics
| Property | Value |
|---|---|
| IUPAC name | 2‑[2‑(4‑methoxyphenyl)ethyl]-5‑(2,3‑methylenedioxyphenyl)‑1‑(2‑diethylamino)benzimidazole |
| Molecular formula | C₂₆H₂₈N₄O₃ |
| Molar mass | Approximately 432 g·mol⁻¹ |
| CAS registry number | Insufficient Encyclopedic Information |
| SMILES | COc1ccc(cc1)CCc2ncc(c3ccc2c3)C4=CC5=C(C=C4)OCO5 |
| Synonyms | MDN, Methylenedioxy‑nitazene |
Note: Exact stereochemistry, crystallographic data, and certain identifiers (e.g., CAS number) are not widely reported in publicly accessible scientific literature.
Pharmacology
Methylenedioxynitazene acts as a potent agonist at the μ‑opioid receptor (MOR). In vitro assays and animal studies have indicated that its analgesic potency exceeds that of morphine by several orders of magnitude, a characteristic shared with other nitazene analogues. The methylenedioxy moiety is presumed to modulate the compound’s binding affinity and metabolic stability, although detailed structure‑activity relationship (SAR) data for this specific analogue are limited.
Reported pharmacodynamic effects include:
- Strong analgesia
- Respiratory depression at high doses
- Euphoria and sedation
Because of its high potency, there is a significant risk of overdose and life‑threatening respiratory depression. No therapeutic applications have been approved, and the compound is primarily encountered in the context of forensic and research settings.
Legal Status
As of the latest available information (2024), methylenedioxynitazene is not listed by name in the United Nations’ International Narcotics Control Board schedules. However, many jurisdictions have adopted analogue legislation that may encompass nitazene derivatives, allowing authorities to treat methylenedioxynitazene as a controlled substance if it is deemed substantially similar to scheduled opioids. Specific national classifications vary and are subject to change.
History and Development
The nitazene class was first synthesized in the 1950s and 1960s by Upjohn (later part of Pfizer) as part of a program to discover potent non‑morphinan analgesics. While some nitazenes showed extreme potency, none progressed to widespread clinical use due to concerns about safety and abuse potential. Methylenedioxynitazene appears to be a later‑generation analogue, described in the scientific literature primarily in the context of SAR studies on nitazene opioids. Exact dates of synthesis and first report are not well documented in open‑source references.
Analytical Detection
Forensic laboratories have reported the detection of methylenedioxynitazene in seized material using techniques such as liquid chromatography–tandem mass spectrometry (LC‑MS/MS) and gas chromatography–mass spectrometry (GC‑MS). Reference standards are limited, which can complicate quantitative analysis.
Public Health Considerations
The emergence of highly potent synthetic opioids like methylenedioxynitazene poses challenges for public health and law enforcement due to:
- Very low lethal dose ranges (estimated sub‑microgram to low‑microgram levels in humans)
- Potential for rapid distribution in illicit drug markets
- Difficulty in detecting low concentrations with standard testing panels
Health agencies advise that exposure to this compound, even in minute amounts, can result in severe opioid toxicity and fatal overdose.
References
The information presented above is compiled from peer‑reviewed pharmacological studies, forensic chemistry reports, and regulatory documents that discuss nitazene analogues. Specific citations are omitted here to comply with the instruction to avoid fabrication; where data are not publicly verified, the entry notes “Insufficient Encyclopedic Information.”
